Trial · NCT03412890
Results by group201
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 201
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of Treatment | Relugolix Plus E2/NETA (Group A) | 86.50 | 95% Confidence Interval 80.28 to 91.34 | percentage of participants | |
| Percentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of Treatment | Relugolix Plus Delayed E2/NETA (Group B) | 79.87 | 95% Confidence Interval 72.52 to 85.98 | percentage of participants | |
| Percentage Of Participants Who Achieved Or Maintained An MBL Volume Of <80 Milliliters (mL) And At Least A 50% Reduction From Baseline MBL Volume At Week 52/End Of Treatment | Placebo (Group C) | 75.00 | 95% Confidence Interval 67.65 to 81.42 | percentage of participants | |
| Change From Pivotal Study Baseline In MBL Volume At Week 52 | Relugolix Plus E2/NETA (Group A) | -251.6 | Standard Error 16.38 | mL | |
| Change From Pivotal Study Baseline In MBL Volume At Week 52 | Relugolix Plus Delayed E2/NETA (Group B) | -219.1 | Standard Error 13.91 | mL | |
| Change From Pivotal Study Baseline In MBL Volume At Week 52 | Placebo (Group C) | -204.7 | Standard Error 13.31 | mL | |
| Percentage Of Participants Who Achieved Or Maintained Amenorrhea Over The Last 35 Days Of Treatment | Relugolix Plus E2/NETA (Group A) | 70.55 | 95% Confidence Interval 62.92 to 77.42 | percentage of participants | |
| Percentage Of Participants Who Achieved Or Maintained Amenorrhea Over The Last 35 Days Of Treatment | Relugolix Plus Delayed E2/NETA (Group B) | 68.46 | 95% Confidence Interval 60.35 to 75.82 | percentage of participants | |
| Percentage Of Participants Who Achieved Or Maintained Amenorrhea Over The Last 35 Days Of Treatment | Placebo (Group C) | 57.93 | 95% Confidence Interval 49.98 to 65.58 | percentage of participants | |
| Percentage Of Participants With A Hemoglobin Level ≤10.5 Gram/Deciliter (g/dL) At Pivotal Study Baseline Who Achieved An Increase Of >2 g/dL From Pivotal Study Baseline At Week 52 | Relugolix Plus E2/NETA (Group A) | 58.97 | 95% Confidence Interval 42.10 to 74.43 | percentage of participants | |
| Percentage Of Participants With A Hemoglobin Level ≤10.5 Gram/Deciliter (g/dL) At Pivotal Study Baseline Who Achieved An Increase Of >2 g/dL From Pivotal Study Baseline At Week 52 | Relugolix Plus Delayed E2/NETA (Group B) | 78.95 | 95% Confidence Interval 62.68 to 90.45 | percentage of participants | |
| Percentage Of Participants With A Hemoglobin Level ≤10.5 Gram/Deciliter (g/dL) At Pivotal Study Baseline Who Achieved An Increase Of >2 g/dL From Pivotal Study Baseline At Week 52 | Placebo (Group C) | 42.11 | 95% Confidence Interval 26.31 to 59.18 | percentage of participants | |
| Number Of Participants With Hemoglobin Increase Of ≥1 g/dL From Pivotal Study Baseline At Week 52 Among Those With A Hemoglobin Concentration Below Lower Limit Of Normal At Pivotal Baseline | Relugolix Plus E2/NETA (Group A) | 56 | participants | ||
| Number Of Participants With Hemoglobin Increase Of ≥1 g/dL From Pivotal Study Baseline At Week 52 Among Those With A Hemoglobin Concentration Below Lower Limit Of Normal At Pivotal Baseline | Relugolix Plus Delayed E2/NETA (Group B) | 60 | participants | ||
| Number Of Participants With Hemoglobin Increase Of ≥1 g/dL From Pivotal Study Baseline At Week 52 Among Those With A Hemoglobin Concentration Below Lower Limit Of Normal At Pivotal Baseline | Placebo (Group C) | 45 | participants | ||
| Change From Pivotal Study Baseline In Hemoglobin Concentration At Week 52 | Relugolix Plus E2/NETA (Group A) | 2.7 | Standard Error 0.24 | g/dL | |
| Change From Pivotal Study Baseline In Hemoglobin Concentration At Week 52 | Relugolix Plus Delayed E2/NETA (Group B) | 3.0 | Standard Error 0.23 | g/dL | |
| Change From Pivotal Study Baseline In Hemoglobin Concentration At Week 52 | Placebo (Group C) | 1.9 | Standard Error 0.22 | g/dL | |
| Change From Pivotal Study Baseline In The UFS-QoL Symptom Severity Scale At Week 52 | Relugolix Plus E2/NETA (Group A) | -37.3 | Standard Error 2.47 | score on a scale | |
| Change From Pivotal Study Baseline In The UFS-QoL Symptom Severity Scale At Week 52 | Relugolix Plus Delayed E2/NETA (Group B) | -38.2 | Standard Error 2.77 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03412890/results